EMEA-002268-PIP03-18
Key facts
| Invented name |
Zejula
|
| Active substance |
Niraparib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0167/2019
|
| PIP number |
EMEA-002268-PIP03-18
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of prostate malignant neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Janssen Research & Development
Tel. +353 857446696 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|